Abstracts tagged "Administrative Data"

Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Patompong Ungprasert¹, Thanat Chaikijurajai², Karn Wijarnpreecha³ and Paul Kroner³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 1609 • ACR Convergence 2020
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen¹, Katrina Rogers² and Charles Inderjeeth¹, ¹The University of Western Australia, Perth, Western Australia, Australia, ²Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…
Abstract Number: 0179 • ACR Convergence 2020
Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning
Bryant England¹, Yangyuna Yang¹, Punyasha Roul¹, Christian Haas², Lotfollah Najjar², Harlan Sayles¹, Fang Yu¹, Brian Sauer³, Joshua Baker⁴, Kaleb Michaud¹, Fenglong Xie⁵, Jeffrey R Curtis⁶ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Omaha, Omaha, NE, ³University of Utah, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Chronic conditions often complicate the disease course of rheumatoid arthritis (RA) and predispose to poor long-term outcomes. The interrelationship of individual chronic conditions and…
Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Joseph Alanaeme¹, Sujith Sarvesh¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Mark Hwang¹, Martin Rozycki², Theresa Arndt², Esther Yi³ and Michael Weisman⁴, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…
Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Yiting Wang¹, Kirsten Lum², Karen Costenbader³, Grace Wang⁴, Jennifer Lofland⁵, Dominik Naessens⁶, Yihan Zhao⁷, Kourtney Davis⁸ and Chetan Karyekar⁹, ¹Janssen Research & Development, LLC, Newark, DE, ²Janssen Pharm Technology - Data Sciences and Data Management, Horsham, PA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Janssen Pharmaceuticals, Horsham, ⁵Janssen Global Market Access, horsham, PA, ⁶Jassen Global Market Access, Beerse, Belgium, ⁷Janssen Pharm Technology - Data Sciences and Data Management, Horsham, ⁸Janssen R&D, LLC, Titusville, NJ, ⁹Janssen Global Services, LLC, Horsham, PA
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…
Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…
Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
Abstract Number: 0269 • ACR Convergence 2020
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
Ehizogie Edigin¹, Precious Eseaton², Pius Ojemolon³ and Augustine Manadan⁴, ¹John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin Teaching Hospital, Benin, ³St. George's University, St. George's, Grenada, ⁴Cook County Hospital/Rush University Medical center, Chicago, IL
Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations…
Abstract Number: 1001 • ACR Convergence 2020
Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Hemin Lee¹, Sarah Chen², Nileesa Gautam², Seanna Vine¹, Mengdong He², Rishi Desai², Michael Weinblatt¹, Robert Glynn² and Seoyoung Kim², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: Previous randomized clinical trials and observational studies have signaled an increased risk of skin cancer in rheumatoid arthritis (RA) patients treated with immunosuppressants such…
Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Abstract Number: 0307 • ACR Convergence 2020
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Alexis Ogdie¹, Martin Rozycki², Theresa Arndt², Cheng Shi³, Nina Kim⁴ and Peter Hur³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴The University of Texas at Austin; Baylor Scott and White Health, Austin, TX
Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
Abstract Number: 1002 • ACR Convergence 2020
Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System
Kaitlyn Brittan¹, Punyasha Roul¹, Joshua Baker², Yangyuna Yang¹, Brian Sauer³, Namrata Singh⁴, Harlan Sayles¹, Grant Cannon⁵, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Utah, Omaha, NE, ⁴University of Washington, Bellevue, WA, ⁵Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Patients with rheumatoid arthritis (RA) may have up to a 15% increased risk of prostate cancer per a recent meta-analysis (Simon et al. Arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].